Sugi Predict

Sugi Predict / Compounds / SCHEMBL187124

SCHEMBL187124

SCHEMBL187124

Cc1ccc(O)c([N+](=O)[O-])n1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CTSB P07858 1/20 0.56
▸ CTSH P09668 1/20 0.56
▸ NPC1 O15118 7/20 0.46
▸ RAB9A P51151 6/20 0.46
▸ SMN1; SMN2 Q16637 4/20 0.44
▸ MAPT P10636 4/20 0.44
▸ S1PR4 O95977 4/20 0.44
▸ ALDH1A1 P00352 6/20 0.44
▸ HTT P42858 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ LMNA P02545 2/20 0.43
▸ HPGD P15428 2/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ GRM5 P41594 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31121580 1.00 CTSB (0.56) CTSBCTSHNPC1RAB9ASMN1; SMN2
SCHEMBL799663 0.79 ALDH1A1 (0.53) CTSBCTSHNPC1RAB9ASMN1; SMN2
SCHEMBL27781678 0.78 CTSB (0.43) CTSBCTSHNPC1RAB9ASMN1; SMN2
SCHEMBL23041103 0.78 ALDH1A1 (0.50) CTSBCTSHNPC1RAB9ASMN1; SMN2
SCHEMBL2638818 0.78 NPC1 (0.47) CTSBCTSHNPC1RAB9ASMN1; SMN2
SCHEMBL29769754 0.78 ALDH1A1 (0.50) CTSBCTSHNPC1RAB9ASMN1; SMN2
SCHEMBL6785310 0.77 ALDH1A1 (0.46) NPC1RAB9ASMN1; SMN2MAPTS1PR4
SCHEMBL10025751 0.76 NPC1 (0.51) NPC1RAB9ASMN1; SMN2MAPTS1PR4
SCHEMBL28051995 0.76 S1PR4 (0.52) NPC1RAB9ASMN1; SMN2MAPTS1PR4
SCHEMBL22530269 0.76 SMN1; SMN2 (0.40) CTSBCTSHNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 378 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108640870-A A method of synthesis 6- bromomethyl -3- methoxyl group -2- nitropyridines 常州大学 2018-10-12 — — CN claimed
US-6176909-B1 IN POLYMERIC BINDER XEROX CORPORATION 2001-01-23 — — US claimed
US-5939568-A Accelerated catalysis of olefinic epoxidations THE SCRIPPS RESEARCH INSTITUTE (US) 1999-08-17 — — US claimed
WO-1998033786-A9 ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS — 1998-12-30 — — WO claimed
WO-1998033786-A1 ACCELERATED CATALYSIS OF OLEFINIC EPOXIDATIONS THE SCRIPPS RESEARCH INSTITUTE (US) 1998-08-06 — — WO claimed
EP-4552697-A2 PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE Novartis AG (CH) 2025-05-14 — — EP disclosed
EP-3514151-B1 PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2025-04-23 — — EP disclosed
CN-119742448-A High-voltage additive for lithium battery electrolyte, electrolyte and lithium ion battery 中国科学院宁波材料技术与工程研究所 2025-04-01 — — CN disclosed
US-20240308979-A1 PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2024-09-19 — — US disclosed
US-20230250095-A1 BENZIMIDAZOLE DERIVATIVES, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF TUOJIE BIOTECH(SHANGHAI) CO., LTD. (CN) 2023-08-10 — — US disclosed
US-20230250095-A1 BENZIMIDAZOLE DERIVATIVES, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF TUOJIE BIOTECH(SHANGHAI) CO., LTD. (CN) 2023-08-10 — — US disclosed
EP-4198034-A1 BENZIMIDAZOLE DERIVATIVES, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF Tuojie Biotech (Shanghai) Co., Ltd. (CN) 2023-06-21 — — EP disclosed
EP-0625143-A1 PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICINES SMITHKLINE BEECHAM INTERCREDIT B.V. (NL) 1994-11-23 — — EP disclosed
WO-1993015055-A1 PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE AS MEDICINES SMITHKLINE BEECHAM INTERCREDIT B.V. (NL) 1993-08-05 — — WO disclosed
US-5190960-A Analgesics ADIR ET COMPAGNIE (FR) 1993-03-02 — — US disclosed
US-5155116-A Analgesics devoid of antiinflammatory activity ADIR ET COMPAGNIE (FR) 1992-10-13 — — US disclosed
US-5084456-A Analgesics SCIENCE ET ORGANISATION (FR) 1992-01-28 — — US disclosed
EP-0463970-A1 Oxazolo pyridine derivatives, process for their preparation and pharmaceutical compositions containing them ADIR ET COMPAGNIE (FR) 1992-01-02 — — EP disclosed
US-4131677-A Anti-inflammatory oxazolo [5,4-b]pyridines MERCK & CO., INC. (US) 1978-12-26 — — US disclosed
US-4038396-A ANTIPYRETICS, ANALGESICS MERCK & CO., INC. (US) 1977-07-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240308979-A1 PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE PRKCA, PRKCB, PRKCH CTSB 2510/4885CTSH 3416/4885NPC1 892/4885
US-20230250095-A1 BENZIMIDAZOLE DERIVATIVES, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF P2RX7, P2RX3, P2RX5 CTSB 1656/4885CTSH 353/4885NPC1 1251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.